Gene therapy for malignant pleural mesothelioma: Present and future

Oncology Research

Volumn 17, Issue 6, 2008, Pages 239-246

  Tada, Yuji ^a   Takiguchi, Yuichi ^a   Hiroshima, Kenzo ^a   Shimada, Hideaki ^a,b   Ueyama, Taro ^a,b   Nakamura, Makoto ^a,b   Tatsumi, Koichiro ^a   Kuriyama, Takayuki ^a   Tagawa, Masatoshi ^a,b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Adenovirus; Clinical trial; Gene therapy; Mesothelioma

Indexed keywords

CYTOKINE; THYMIDINE KINASE;

CLINICAL TRIAL; GENE THERAPY; GENETICS; HUMAN; IMMUNOTHERAPY; MESOTHELIOMA; METABOLISM; METHODOLOGY; PLEURA TUMOR; REVIEW; TUMOR SUPPRESSOR GENE;

CLINICAL TRIALS AS TOPIC; CYTOKINES; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOTHERAPY; MESOTHELIOMA; PLEURAL NEOPLASMS; THYMIDINE KINASE;

EID: 61449113085     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504008786991602     Document Type: Review

References (39)

1. Testa, J. R.; Carbone, M.; Hirvonen, A.; Khalili, K.; Krynska, B.; Linnainmaa, K.; Pooley, F. D.; Rizzo, P.; Rusch, V.; Xiao, G. H. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res. 58:4505-4509; 1998.
2. Robinson, B. W.; Musk, A. W.; Lake, R. A. Malignant mesothelioma. Lancet 366:397-408; 2005.
3. Robinson, B. W.; Lake, R. A. Advances in malignant mesothelioma. N. Engl. J. Med. 353:1591-1603; 2005.
4. Vogelzang, N. J.; Rusthoven, J. J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C.; Niyikiza, C.; Paoletti, P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21:2636-2644; 2003.
5. Kucharczuk, J. C.; Raper, S.; Elshami, A. A.; Amin, K. M.; Sterman, D. H.; Wheeldon, E. B.; Wilson, J. M.; Litzky, L. A.; Kaiser, L. R.; Albelda, S. M. Safety of in- trapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. Hum. Gene Ther. 7:2225-2233; 1996.
6. Schwarzenberger, P.; Harrison, L.; Weinacker, A.; Marrogi, A.; Byrne, P.; Ramesh, R.; Theodossiou, C.; Gaumer, R.; Summer, W.; Freeman, S. M.; Kolls, J. K. The treatment of malignant mesothelioma with a gene modified cancer cell line. A phase I study. Hum. Gene Ther. 9:2641-2649; 1998.
7. Harrison, Jr., L. H.; Schwarzenberger, P. O.; Byrne, P. S.; Marrogi, A. J.; Kolls, J. K.; McCarthy, K. E. Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann. Thorac. Surg. 70: 407-411; 2000.
8. Mukherjee, S.; Haenel, T.; Himbeck, R.; Scott, B.; Ramshaw, I.; Lake, R. A.; Harnett, G.; Phillips, P.; Morey, S.; Smith, D.; Davidson, J. A.; Musk, A. W.; Robinson, B. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer. Persistent transgene expression despite antibody generation. Cancer Gene Ther. 7: 663-670; 2000.
9. Sterman, D. H.; Recio, A.; Carroll, R. G.; Gillespie, C. T.; Haas, A.; Vachani, A.; Kapoor, V.; Sun, J.; Hodinka, R.; Brown, J. L.; Corbley, M. J.; Parr, M.; Ho, M.; Pastan, I.; Machuzak, M.; Benedict, W.; Zhang, X. Q.; Lord, E. M.; Litzky, L. A.; Heitjan, D. F.; June, C. H.; Kaiser, L. R.; Vonderheide, R. H.; Albelda, S. M.; Kanther, M. A phase I clinical trial of single-dose intrapleural IFN-β gene transfer for malignant pleural mesothelioma and met- astatic pleural effusions: High rate of antitumor immune responses. Clin. Cancer Res. 13:4456-4466; 2007.
10. Sterman, D. H.; Treat, J.; Litzky, L. A.; Amin, K. M.; Coonrod, L.; Molnar-Kimber, K.; Recio, A.; Knox, L.; Wilson, J. M.; Albelda, S. M.; Kaiser, L. R. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9:1083- 1092; 1998.
11. Sterman, D. H.; Recio, A.; Vachani, A.; Sun, J.; Cheung, L.; DeLong, P.; Amin, K. M.; Litzky, L. A.; Wilson, J. M.; Kaiser, L. R.; Albelda, S. M. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ ganciclovir suicide gene therapy. Clin. Cancer Res. 11: 7444-7453; 2005.
12. Esandi, M. C.; van Someren, G. D.; Vincent, A. J.; van Bekkum, D. W.; Valerio, D.; Bout, A.; Noteboom, J. L. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther. 4:280-287; 1997.
13. Lambright, E. S.; Force, S. D.; Lanuti, M. E.; Wasfi, D. S.; Amin, K. M.; Albelda, S. M.; Kaiser, L. R. Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model. Ann. Thorac. Surg. 70:1865-1871; 2000.
14. Berlinghoff, S.; Veldwijk, M. R.; Laufs, S.; Maser, H. P.; Jauch, A.; Wenz, F.; Zeller, W. J.; Fruehauf, S. Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy. Lung Cancer 46: 179-186; 2004. (Pubitemid 39330412)
15. Molnar-Kimber, K. L.; Sterman, D. H.; Chang, M.; Kang, E. H.; ElBash, M.; Lanuti, M.; Elshami, A.; Gelfand, K.; Wilson, J. M.; Kaiser, L. R.; Albelda, S. M. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9: 2121-2133; 1998.
16. Sterman, D. H.; Molnar-Kimber, K.; Iyengar, T.; Chang, M.; Lanuti, M.; Amin, K. M.; Pierce, B. K.; Kang, E.; Treat, J.; Recio, A.; Litzky, L.; Wilson, J. M.; Kaiser, L. R.; Albelda, S. M. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adeno- viral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther. 7:1511-1518; 2000.
17. Rainov, N. G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11:2389-2401; 2000.
18. Kumar-Singh, S.; Weyler, J.; Martin, M. J.; Vermeulen, P. B.; Van Marck, E. Angiogenic cytokines in mesothelioma: A study of VEGF, FGF-1 and -2, and TGF beta expression. J. Pathol. 189:72-78; 1999.
19. Kruklitis, R. J.; Singhal, S.; Delong, P.; Kapoor, V.; Sterman, D. H.; Kaiser, L. R.; Albelda, S. M. Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J. Thorac. Cardiovasc. Surg. 127:123-130; 2004.
20. Gattacceca, F.; Pilatte, Y.; Billard, C.; Monnet, I.; Moritz, S.; Le Carrou, J.; Eloit, M.; Jaurand, M. C. Ad-IFN γ induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin. Cancer Res. 8:3298-3304; 2002.
21. Caminschi, I.; Venetsanakos, E.; Leong, C. C.; Garlepp, M. J.; Robinson, B. W.; Scott, B. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12. Am. J. Respir. Cell. Mol. Biol. 21: 347-356; 1999.
22. Tada, Y.; O-Wang, J.; Yu, L.; Shimozato, O.; Wang, Y. Q.; Takiguchi, Y.; Tatsumi, K.; Kuriyama, T.; Takenaga, K.; Sakiyama, S.; Tagawa, M. T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines. Cancer Gene Ther. 10:451-456; 2003. (Pubitemid 36667131)
23. Friedlander, P. L.; Delaune, C. L.; Abadie, J. M.; Toups, M.; LaCour, J.; Marrero, L.; Zhong, Q.; Kolls, J. K. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am. J. Respir. Cell. Mol. Biol. 29:321-330; 2003.
24. Okada, M.; Wiewrodt, R.; DeLong, P.; Tanaka, T.; Zhang, Y.; Kaiser, L.; Albelda, S. Analysis of the immunologic response generated by Ad.IFN-β during successful intra-peritoneal tumor gene therapy. Mol. Ther. 6:210-218; 2002.
25. Yang, C. T.; You, L.; Yeh, C. C.; Chang, J. W.; Zhang, F.; McCormick, F.; Jablons, D. M. Adenovirus-mediated p14ARF gene transfer in human mesothelioma cells. J. Natl. Cancer Inst. 92:636-641; 2000.
26. Yang, C. T.; You, L.; Uematsu, K.; Yeh, C. C.; McCormick, F.; Jablons, D. M. p14 (ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. 61:5959-5963; 2001.
27. Frizelle, S. P.; Grim, J.; Zhou, J.; Gupta, P.; Curiel, D. T.; Geradts, J.; Kratzke, R. A. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 16: 3087-3095; 1998.
28. INK4a adenovirus. Cancer Gene Ther. 7:1421-1425; 2000.
29. Lin, E.; Nemunaitis, J. Oncolytic viral therapies. Cancer Gene Ther. 11:643-664; 2004.
30. Mohiuddin, I.; Cao, X.; Fang, B.; Nishizaki, M.; Smythe, W. R. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther. 8:547-554; 2001.
31. Cao, X. X.; Mohuiddin, I.; Chada, S.; Mhashilkar, A. M.; Ozvaran, M. K.; McConkey, D. J.; Miller, S. D.; Daniel, J. C.; Smythe, W. R. Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL. Mol. Med. 8:869-876; 2002.
32. Hassan, R.; Bera, T.; Pastan, I. Mesothelin: A new target for immunotherapy. Clin. Cancer Res. 10:3937-3942; 2004.
33. Shaw, D. R.; Muminova, Z. E.; Strong, T. V. Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 10: 8751-8752; 2004.
34. Xia, C.; Xu, Z.; Yuan, X.; Uematsu, K.; You, L.; Li, K.; Li, L.; McCormick, F.; Jablons, D. M. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol. Cancer Ther. 1:687-694; 2002.
35. Zhu, Z. B.; Makhija, S. K.; Lu, B.; Wang, M.; Rivera, A. A.; Kim-Park, S.; Ulasov, I. V.; Zhou, F.; Alvarez, R. D.; Siegal, G. P.; Curiel, D. T. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int. J. Oncol. 27:237-246; 2005.
36. Masood, R.; Kundra, A.; Zhu, S.; Xia, G.; Scalia, P.; Smith, D. L.; Gill, P. S. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int. J. Cancer 104:603-610; 2003.
37. Li, Q.; Yano, S.; Ogino, H.; Wang, W.; Uehara, H.; Nishioka, Y.; Sone, S. The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin. Cancer Res. 13:5918-5925; 2007.
38. Lee, A. Y.; Raz, D. J.; He, B.; Jablons, D. M. Update on the molecular biology of malignant mesothelioma. Cancer 109:1454-1461; 2007.
39. Lanuti, M.; Kouri, C. E.; Force, S.; Chang, M.; Amin, K.; Xu, K.; Blair, I.; Kaiser, L.; Albelda, S. Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Ther. 6:1600-1610; 1999.